24 September 2015 - The Canadian Drug Expert Committee (CDEC) of CADTH has recommended the reimbursement of the following products:

• Aclidinium bromide with eformoterol fumarate dihydrate (Duaklir Genuair) - adults with chronic obstructive pulmonary disease
• Daclatasvir dihydrochloride (Daklinza) - use in combination with sofosbuvir by patients with genotype 3 chronic hepatitis C virus infection
• Denosumab (Prolia) - men with osteoporosis
• Umeclidinium bromide (Incruse Ellipta) - adults with chronic obstuctive pulmonary disease

For more details, go to: https://www.cadth.ca